---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-038861"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:17:47.665727+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health shareholders OK reverse stock split; crofelemer POC data and FDA meeting expected Q2 2025

## Summary
- Shareholders voted 5,281,329 for and 1,377,494 against the reverse stock split (ratio 1:15 to 1:40); board to set exact ratio by March 2026.
- First proof-of-concept investigator-initiated trial results for crofelemer in SBS-IF and MVID are expected in Q2 2025.
- Company expects FDA meeting in Q2 2025 to discuss Phase 3 OnTarget breast cancer subgroup results and potential approval path.
- Adjournment proposal also approved with 5,423,671 for and 1,163,222 against.

## SEC filing metadata
- accession: 0000950170-25-038861
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000095017025038861/0000950170-25-038861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000095017025038861/jagx-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-038861
- JSON: https://secwatch.observer/filing/0000950170-25-038861.json
- Plain text: https://secwatch.observer/filing/0000950170-25-038861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.